Prognostic value of HALP score in predicting in-hospital mortality in patients with NSTEMI.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-02-26 DOI:10.1080/17520363.2025.2468144

Dogan Ilis, Ayca Arslan, Inanc Artac, Muammer Karakayali, Timor Omar, Serif Hamideyin, Hatice Taşkan, Ozcan Yagicibulut, Yavuz Karabag, Ibrahim Rencuzogullari

{"title":"Prognostic value of HALP score in predicting in-hospital mortality in patients with NSTEMI.","authors":"Dogan Ilis, Ayca Arslan, Inanc Artac, Muammer Karakayali, Timor Omar, Serif Hamideyin, Hatice Taşkan, Ozcan Yagicibulut, Yavuz Karabag, Ibrahim Rencuzogullari","doi":"10.1080/17520363.2025.2468144","DOIUrl":null,"url":null,"abstract":"Aims: We aimed to investigate the association between the HALP score and in-hospital mortality in patients with non-ST segment myocardial infarction (NSTEMI).Materials and methods: In this retrospective study participants were divided into two groups, based on the median HALP score. Findings were compared between the groups.Results: A total of 1648 patients included. The median HALP score cutoff value was 3.87. While the low HALP score group (<3.87) included 824 patients, the high HALP score group (>3.87) included 824 patients. Patients with the low HALP score were older and had a higher prevalence of comorbidities. A HALP score ≤ 2.62 predicted in-hospital mortality with sensitivity of 72.5% and a specificity of 77.3% (area under curve 0.809), according to ROC curve analysis. In multivariate analysis, age, diastolic blood pressure, Killip Class > 1 and Syntax Score, creatinine level, LVEF and HALP Score (OR: 0.504, 95% CI: 0.415-0.613; p < 0.001) were independently associated with in-hospital mortality.Conclusions: According to the current study, the HALP score was independently associated with in-hospital mortality in patients with NSTEMI. Moreover, HALP score might be used as a predictor of in-hospital mortality in this population.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-9"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2468144","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: We aimed to investigate the association between the HALP score and in-hospital mortality in patients with non-ST segment myocardial infarction (NSTEMI).

Materials and methods: In this retrospective study participants were divided into two groups, based on the median HALP score. Findings were compared between the groups.

Results: A total of 1648 patients included. The median HALP score cutoff value was 3.87. While the low HALP score group (<3.87) included 824 patients, the high HALP score group (>3.87) included 824 patients. Patients with the low HALP score were older and had a higher prevalence of comorbidities. A HALP score ≤ 2.62 predicted in-hospital mortality with sensitivity of 72.5% and a specificity of 77.3% (area under curve 0.809), according to ROC curve analysis. In multivariate analysis, age, diastolic blood pressure, Killip Class > 1 and Syntax Score, creatinine level, LVEF and HALP Score (OR: 0.504, 95% CI: 0.415-0.613; p < 0.001) were independently associated with in-hospital mortality.

Conclusions: According to the current study, the HALP score was independently associated with in-hospital mortality in patients with NSTEMI. Moreover, HALP score might be used as a predictor of in-hospital mortality in this population.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.